REPLIGEN CORP Deferred Tax Assets, Tax Deferred Expense, Other
REPLIGEN CORP (RGEN) had Deferred Tax Assets, Tax Deferred Expense, Other of $12.68 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $12.68M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $11.59M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $7.06M; Deferred Tax Assets, Tax Deferred Expense, Other as first filed $5.31M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $6.06M; Deferred Tax Assets, Tax Deferred Expense, Other as first filed $4.44M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other | Deferred Tax Assets, Tax Deferred Expense, Other as first filed |
|---|---|---|
| 2025-12-31 | $12.68M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $11.59M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $7.06M 10-K · filed 2025-03-14 | $5.31M 10-K · filed 2024-02-22 |
| 2022-12-31 | $6.06M 10-K/A · filed 2024-11-18 | $4.44M 10-K · filed 2023-02-22 |
| 2021-12-31 | $3.50M 10-K · filed 2023-02-22 | $6.59M 10-K · filed 2022-02-17 |
| 2020-12-31 | $5.77M 10-K · filed 2022-02-17 | $5.75M 10-K · filed 2021-02-24 |
| 2019-12-31 | $4.99M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $3.58M 10-K · filed 2020-02-26 | $2.63M 10-K · filed 2019-03-01 |
| 2017-12-31 | $1.70M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $1.90M 10-K · filed 2018-02-22 | |
| 2015-12-31 | $1.15M 10-K · filed 2017-02-23 | |
| 2014-12-31 | $1.67M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |